Publications

2023

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich TMP, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Burton EA, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin AD. Gynecol Oncol. 2023 May; 2023 Mar 21. PMID: 36958197.
Cryo-EM analyses of KIT and oncogenic mutants reveal structural oncogenic plasticity and a target for therapeutic intervention.Krimmer SG, Bertoletti N, Suzuki Y, Katic L, Mohanty J, Shu S, Lee S, Lax I, Mi W, Schlessinger J. Proc Natl Acad Sci U S A. 2023 Mar 28; 2023 Mar 21. PMID: 36943885.
Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies.Edman NI, Redler RL, Phal A, Schlichthaerle T, Srivatsan SR, Etemadi A, An S, Favor A, Ehnes D, Li Z, Praetorius F, Gordon M, Yang W, Coventry B, Hicks DR, Cao L, Bethel N, Heine P, Murray AN, Gerben S, Carter L, Miranda M, Negahdari B, Lee S, Trapnell C, Stewart L, Ekiert DC, Schlessinger J, Shendure J, Bhabha G, Ruohola-Baker H, Baker D. bioRxiv. 2023 Mar 15; 2023 Mar 15. PMID: 36993355.
Acne Vulgaris.Sutaria AH, Masood S, Schlessinger J. 2023 Jan. PMID: 29083670.
Heparin is essential for optimal cell signaling by FGF21 and for regulation of βKlotho cellular stability.An SJ, Mohanty J, Tome F, Suzuki Y, Lax I, Schlessinger J. Proc Natl Acad Sci U S A. 2023 Feb 14; 2023 Feb 6. PMID: 36745784.
Biochemistry, Melanin.Schlessinger DI, Anoruo M, Schlessinger J. 2023 Jan. PMID: 29083759.
Chloracne.Schlessinger DI, Robinson CA, Schlessinger J. 2023 Jan. PMID: 29083575.
Solar Urticaria.Harris BW, Crane JS, Schlessinger J. 2023 Jan. PMID: 28723015.

2022

Unveiling molecular insights into the mechanism of activation of oncogenic phosphoinositide 3-kinase mutants.Krimmer SG, Schlessinger J. Proc Natl Acad Sci U S A. 2022 Dec 13; 2022 Dec 7. PMID: 36475945.
Regulation of EGF-stimulated activation of the PI-3K/AKT pathway by exocyst-mediated exocytosis.An SJ, Anneken A, Xi Z, Choi C, Schlessinger J, Toomre D. Proc Natl Acad Sci U S A. 2022 Nov 29; 2022 Nov 23. PMID: 36417441.
Covalent Modification of the JH2 Domain of Janus Kinase 2.Henry SP, Liosi ME, Ippolito JA, Menges F, Newton AS, Schlessinger J, Jorgensen WL. ACS Med Chem Lett. 2022 Nov 10; 2022 Oct 24. PMID: 36385940.
Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein.Park JS, Choi J, Cao L, Mohanty J, Suzuki Y, Park A, Baker D, Schlessinger J, Lee S. Cell Rep. 2022 Oct 25. PMID: 36288716.
Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.Liosi ME, Ippolito JA, Henry SP, Krimmer SG, Newton AS, Cutrona KJ, Olivarez RA, Mohanty J, Schlessinger J, Jorgensen WL. J Med Chem. 2022 Jun 23; 2022 Jun 2. PMID: 35653642.
Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials.Bass LS, Kaufman-Janette J, Joseph JH, Kaminer MS, Clark J, Fabi SG, Gold MH, Katz BE, Peddy K, Schlessinger J, Young VL, Hurley D, McLane MP, Vijayan S, Liu G, Davis MW, Goldman MP. Plast Reconstr Surg Glob Open. 2022 May; 2022 May 25. PMID: 35646496.
Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.Henry SP, Liosi ME, Ippolito JA, Cutrona KJ, Krimmer SG, Newton AS, Schlessinger J, Jorgensen WL. ACS Med Chem Lett. 2022 May 12; 2022 Apr 21. PMID: 35586418.
Design of protein-binding proteins from the target structure alone.Cao L, Coventry B, Goreshnik I, Huang B, Sheffler W, Park JS, Jude KM, Marković I, Kadam RU, Verschueren KHG, Verstraete K, Walsh STR, Bennett N, Phal A, Yang A, Kozodoy L, DeWitt M, Picton L, Miller L, Strauch EM, DeBouver ND, Pires A, Bera AK, Halabiya S, Hammerson B, Yang W, Bernard S, Stewart L, Wilson IA, Ruohola-Baker H, Schlessinger J, Lee S, Savvides SN, Garcia KC, Baker D. Nature. 2022 May; 2022 Mar 24. PMID: 35332283.
A hypothalamic pathway for Augmentor α-controlled body weight regulation.Ahmed M, Kaur N, Cheng Q, Shanabrough M, Tretiakov EO, Harkany T, Horvath TL, Schlessinger J. Proc Natl Acad Sci U S A. 2022 Apr 19; 2022 Apr 11. PMID: 35412887.
Safety and Effectiveness of a Novel Hyaluronic Acid Gel for Lip Augmentation.Adelglass J, Alonso-Llamazares J, Fenton J, Gold M, Schlessinger J, Smith S. J Drugs Dermatol. 2022 Jan 1. PMID: 35005871.
Efficacy and Safety of a New Resilient Hyaluronic Acid Filler in the Correction of Moderate-to-Severe Dynamic Perioral Rhytides: A 52-Week Prospective, Multicenter, Controlled, Randomized, Evaluator-Blinded Study.Sundaram H, Shamban A, Schlessinger J, Kaufman-Janette J, Joseph JH, Lupin M, Draelos Z, Carey W, Smith S, Eaton L. Dermatol Surg. 2022 Jan 1. PMID: 34608092.

2021

Mechanism for the activation of the anaplastic lymphoma kinase receptor.Reshetnyak AV, Rossi P, Myasnikov AG, Sowaileh M, Mohanty J, Nourse A, Miller DJ, Lax I, Schlessinger J, Kalodimos CG. Nature. 2021 Dec; 2021 Nov 24. PMID: 34819673.
Structural basis for ligand reception by anaplastic lymphoma kinase.Li T, Stayrook SE, Tsutsui Y, Zhang J, Wang Y, Li H, Proffitt A, Krimmer SG, Ahmed M, Belliveau O, Walker IX, Mudumbi KC, Suzuki Y, Lax I, Alvarado D, Lemmon MA, Schlessinger J, Klein DE. Nature. 2021 Dec; 2021 Nov 24. PMID: 34819665.
Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.Kaufman-Janette J, Avelar RL, Biesman BS, Draelos ZD, Gross JE, Jones DH, Lupo MP, Maas CS, Schlessinger J, Shamban AT, Sundaram H, Weinkle SH, Young VL. Aesthet Surg J. 2021 Nov 12. PMID: 34309676.
Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.Lorenc ZP, Adelglass JM, Avelar RL, Baumann L, Beer KR, Cohen JL, Cox SE, Dayan SH, Dover JS, Downie JB, Draelos ZD, Goldman MP, Gross JE, Joseph JH, Kaufman-Janette J, Moy RL, Nestor M, Schlessinger J, Smith SR, Weiss RA. Aesthet Surg J. 2021 Nov 12. PMID: 34189562.
The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.Lorenc ZP, Adelglass JM, Avelar RL, Baumann L, Beer KR, Cohen JL, Cox SE, Dayan SH, Dover JS, Downie JB, Draelos ZD, Goldman MP, Gross JE, Joseph JH, Kaufman-Janette J, Moy RL, Nestor M, Schlessinger J, Smith SR, Weiss RA. Aesthet Surg J. 2021 Nov 12. PMID: 33944913.
The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.Kaufman-Janette J, Avelar RL, Biesman BS, Draelos ZD, Gross JE, Jones DH, Lupo MP, Maas CS, Schlessinger J, Shamban AT, Sundaram H, Weinkle SH, Young VL. Aesthet Surg J. 2021 Nov 12. PMID: 33944905.
AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data.Schlessinger J, Friedmann DP, Mayoral F, Mraz Robinson D, Glaser D, Wu D, Marcus K, Somenek M, Lin X. J Drugs Dermatol. 2021 Sep 1. PMID: 34491022.
Indoloxytriazines as binding molecules for the JAK2 JH2 pseudokinase domain and its V617F variant.Newton AS, Liosi ME, Henry SP, Deiana L, Faver JC, Krimmer SG, Puleo DE, Schlessinger J, Jorgensen WL. Tetrahedron Lett. 2021 Aug 3; 2021 Jul 2. PMID: 34393283.
Collagenase Clostridium Histolyticum-aaes for the Treatment of Cellulite in Women: Results From Two Phase 3 Randomized, Placebo-Controlled Trials.Kaufman-Janette J, Joseph JH, Kaminer MS, Clark J, Fabi SG, Gold MH, Goldman MP, Katz BE, Peddy K, Schlessinger J, Young VL, Davis M, Hurley D, Liu G, McLane MP, Vijayan S, Bass LS. Dermatol Surg. 2021 May 1. PMID: 33840781.
Integrated mutational landscape analysis of uterine leiomyosarcomas.Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Proc Natl Acad Sci U S A. 2021 Apr 13. PMID: 33876771.
A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines.Schlessinger J, Cohen JL, Shamban A, Jacob C, Karimi K, Maas C, Lane V, Coquis-Knezek S, Meckfessel M. Dermatol Surg. 2021 Apr 1. PMID: 33165057.
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR. N Engl J Med. 2021 Feb 11. PMID: 33567191.
Aesthetic Office Disaster Preparedness and Response Plan.Cohen JL, Dayan SH, Avram MM, Saltz R, Kilmer S, Maas CS, Schlessinger J. J Drugs Dermatol. 2021 Jan 1. PMID: 33400419.

2020

Scaffold association factor B (SAFB) is required for expression of prenyltransferases and RAS membrane association.Zhou M, Kuruvilla L, Shi X, Viviano S, Ahearn IM, Amendola CR, Su W, Badri S, Mahaffey J, Fehrenbacher N, Skok J, Schlessinger J, Turk BE, Calderwood DA, Philips MR. Proc Natl Acad Sci U S A. 2020 Dec 15; 2020 Nov 30. PMID: 33257571.
FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho.Suzuki Y, Kuzina E, An SJ, Tome F, Mohanty J, Li W, Lee S, Liu Y, Lax I, Schlessinger J. Proc Natl Acad Sci U S A. 2020 Dec 15; 2020 Nov 30. PMID: 33257569.
Hydrogen Peroxide Topical Solution, 45% for Common Warts: Phase 2 Efficacy and Safety Trial Results.Smith SR, Tyring SK, Grande KK, Schlessinger J, Gold MH, Shanier SD. J Drugs Dermatol. 2020 Oct 1. PMID: 33026766.
Nashville, Tennessee, December 4-7, 2019.Schlessinger J. Skinmed. 2020; 2020 Aug 1. PMID: 33032688.
Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.Liosi ME, Krimmer SG, Newton AS, Dawson TK, Puleo DE, Cutrona KJ, Suzuki Y, Schlessinger J, Jorgensen WL. J Med Chem. 2020 May 28; 2020 May 8. PMID: 32329617.
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, Ports WC, Purohit V, Takiya L, Werth JL, Zang C, Vlahos B. Am J Clin Dermatol. 2020 Apr. PMID: 32212104.
DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).Bertucci V, Solish N, Kaufman-Janette J, Yoelin S, Shamban A, Schlessinger J, Snyder D, Gallagher C, Liu Y, Shears G, Rubio RG. J Am Acad Dermatol. 2020 Apr; 2019 Nov 29. PMID: 31791824.
Commentary on Microcannula Injection of Large Gel Particle Hyaluronic Acid for Cheek Augmentation and the Correction of Age-Related Midface Contour Deficiencies.Schlessinger DI, Schlessinger J. Dermatol Surg. 2020 Apr. PMID: 31574035.
Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis.Abramovits W, Schlessinger J. J Drugs Dermatol. 2020 Mar 1. PMID: 32550687.
DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).Carruthers JD, Fagien S, Joseph JH, Humphrey SD, Biesman BS, Gallagher CJ, Liu Y, Rubio RG. Plast Reconstr Surg. 2020 Jan. PMID: 31609882.

2019

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Proc Natl Acad Sci U S A. 2019 Nov 5; 2019 Oct 17. PMID: 31624127.
Small molecule combats cancer-causing KRAS protein at last.Herbst RS, Schlessinger J. Nature. 2019 Nov. PMID: 31705127.
Safety and Effectiveness of Microfocused Ultrasound for Treating Erythematotelangiectatic Rosacea.Schlessinger J, Lupin M, McDaniel D, George R. J Drugs Dermatol. 2019 Jun 1. PMID: 31251544.
Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity.Kuzina ES, Ung PM, Mohanty J, Tome F, Choi J, Pardon E, Steyaert J, Lax I, Schlessinger A, Schlessinger J, Lee S. Proc Natl Acad Sci U S A. 2019 Apr 16; 2019 Apr 3. PMID: 30944224.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD. Proc Natl Acad Sci U S A. 2019 Jan 8; 2018 Dec 24. PMID: 30584090.
Final Data from the Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR).Palm MD, Schlessinger J, Callender VD, Fagien S, Beer K, Magante S, Sangha S. J Drugs Dermatol. 2019 Jan 1. PMID: 30681793.

2018

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302).Baumann LS, Blauvelt A, Draelos ZD, Kempers SE, Lupo MP, Schlessinger J, Smith SR, Wilson DC, Bradshaw M, Estes E, Shanler SD. J Am Acad Dermatol. 2018 Nov; 2018 Jun 1. PMID: 29864467.
Reminiscences on the "Classic" 1976 FRAP Article in Biophysical Journal.Axelrod D, Elson EL, Schlessinger J, Koppel DE. Biophys J. 2018 Oct 2; 2018 Sep 4. PMID: 30224052.
Self-reported Patient Motivations for Seeking Cosmetic Procedures.Maisel A, Waldman A, Furlan K, Weil A, Sacotte K, Lazaroff JM, Lin K, Aranzazu D, Avram MM, Bell A, Cartee TV, Cazzaniga A, Chapas A, Crispin MK, Croix JA, DiGiorgio CM, Dover JS, Goldberg DJ, Goldman MP, Green JB, Griffin CL, Haimovic AD, Hausauer AK, Hernandez SL, Hsu S, Ibrahim O, Jones DH, Kaufman J, Kilmer SL, Lee NY, McDaniel DH, Schlessinger J, Tanzi E, Weiss ET, Weiss RA, Wu D, Poon E, Alam M. JAMA Dermatol. 2018 Oct 1. PMID: 30140900.
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD. Clin Cancer Res. 2018 Oct 1; 2018 Jun 25. PMID: 29941483.
Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials.Dayan SH, Schlessinger J, Beer K, Donofrio LM, Jones DH, Humphrey S, Carruthers J, Lizzul PF, Gross TM, Beddingfield FC 3rd, Somogyi C. Aesthet Surg J. 2018 Aug 16. PMID: 29401213.
Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).Reshetnyak AV, Mohanty J, Tomé F, Puleo DE, Plotnikov AN, Ahmed M, Kaur N, Poliakov A, Cinnaiyan AM, Lax I, Schlessinger J. Proc Natl Acad Sci U S A. 2018 Aug 14; 2018 Jul 30. PMID: 30061385.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA. Nat Commun. 2018 Aug 10; 2018 Aug 10. PMID: 30097571.
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Ann Oncol. 2018 Apr 1. PMID: 29688333.
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG, Meng X, Guana A, Nyirady J. Dermatol Ther (Heidelb). 2018 Mar; 2017 Dec 7. PMID: 29218492.
Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.Lee S, Choi J, Mohanty J, Sousa LP, Tome F, Pardon E, Steyaert J, Lemmon MA, Lax I, Schlessinger J. Nature. 2018 Jan 25; 2018 Jan 17. PMID: 29342135.
A Multicenter, Double-Blinded, Randomized, Split-Face Study of the Safety and Efficacy of a Novel Hyaluronic Acid Gel for the Correction of Nasolabial Folds.Gold MH, Baumann LS, Clark CP III, Schlessinger J. J Drugs Dermatol. 2018 Jan 1. PMID: 29320589.

2017

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Cancer Discov. 2017 Dec; 2017 Oct 12. PMID: 29025772.
Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk.Mo ES, Cheng Q, Reshetnyak AV, Schlessinger J, Nicoli S. Proc Natl Acad Sci U S A. 2017 Nov 7; 2017 Oct 23. PMID: 29078341.
Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.Puleo DE, Kucera K, Hammarén HM, Ungureanu D, Newton AS, Silvennoinen O, Jorgensen WL, Schlessinger J. ACS Med Chem Lett. 2017 Jun 8; 2017 May 17. PMID: 28626521.
JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.Newton AS, Deiana L, Puleo DE, Cisneros JA, Cutrona KJ, Schlessinger J, Jorgensen WL. ACS Med Chem Lett. 2017 Jun 8; 2017 May 17. PMID: 28626520.
New Uses of AbobotulinumtoxinA in Aesthetics.Schlessinger J, Gilbert E, Cohen JL, Kaufman J. Aesthet Surg J. 2017 May 1. PMID: 28388720.
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Ann Oncol. 2017 Jan 1. PMID: 28177435.
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Ann Oncol. 2017 Jan 1. PMID: 27687306.

2016

Split-Face Comparison of an Advanced Non-Hydroquinone Lightening Solution to 4% Hydroquinone.Schlessinger J, Saxena S, Mohr S. J Drugs Dermatol. 2016 Dec 1. PMID: 28095580.
Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, Lifton RP. Clin Cancer Res. 2016 Dec 1; 2016 Aug 2. PMID: 27486176.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Proc Natl Acad Sci U S A. 2016 Oct 25; 2016 Oct 10. PMID: 27791010.
Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.Shi X, Sousa LP, Mandel-Bausch EM, Tome F, Reshetnyak AV, Hadari Y, Schlessinger J, Lax I. Proc Natl Acad Sci U S A. 2016 Aug 16; 2016 Aug 1. PMID: 27482095.
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.Shi X, Mihaylova VT, Kuruvilla L, Chen F, Viviano S, Baldassarre M, Sperandio D, Martinez R, Yue P, Bates JG, Breckenridge DG, Schlessinger J, Turk BE, Calderwood DA. Proc Natl Acad Sci U S A. 2016 Aug 2; 2016 Jul 18. PMID: 27432991.
7th Annual Cosmetic Surgery Forum 2015.Schlessinger J. Skinmed. 2016; 2016 Aug 1. PMID: 27784522.
Assessment of a Novel Anti-Aging Hand Cream.Schlessinger J, Saxena S, Mohr S. J Drugs Dermatol. 2016 Apr. PMID: 27050706.
Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain.Kobashigawa Y, Amano S, Yoza K, Himeno R, Amemiya S, Morioka H, Yokogawa M, Kumeta H, Schlessinger J, Inagaki F. Genes Cells. 2016 Apr; 2016 Feb 10. PMID: 26864631.
The Dark Side of Cell Signaling: Positive Roles for Negative Regulators.Lemmon MA, Freed DM, Schlessinger J, Kiyatkin A. Cell. 2016 Mar 10. PMID: 26967284.
Data publication with the structural biology data grid supports live analysis.Meyer PA, Socias S, Key J, Ransey E, Tjon EC, Buschiazzo A, Lei M, Botka C, Withrow J, Neau D, Rajashankar K, Anderson KS, Baxter RH, Blacklow SC, Boggon TJ, Bonvin AM, Borek D, Brett TJ, Caflisch A, Chang CI, Chazin WJ, Corbett KD, Cosgrove MS, Crosson S, Dhe-Paganon S, Di Cera E, Drennan CL, Eck MJ, Eichman BF, Fan QR, Ferré-D'Amaré AR, Fromme JC, Garcia KC, Gaudet R, Gong P, Harrison SC, Heldwein EE, Jia Z, Keenan RJ, Kruse AC, Kvansakul M, McLellan JS, Modis Y, Nam Y, Otwinowski Z, Pai EF, Pereira PJ, Petosa C, Raman CS, Rapoport TA, Roll-Mecak A, Rosen MK, Rudenko G, Schlessinger J, Schwartz TU, Shamoo Y, Sondermann H, Tao YJ, Tolia NH, Tsodikov OV, Westover KD, Wu H, Foster I, Fraser JS, Maia FR, Gonen T, Kirchhausen T, Diederichs K, Crosas M, Sliz P. Nat Commun. 2016 Mar 7; 2016 Mar 7. PMID: 26947396.
Early and multiple origins of metastatic lineages within primary tumors.Zhao ZM, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL, Townsend JP. Proc Natl Acad Sci U S A. 2016 Feb 23; 2016 Feb 8. PMID: 26858460.
A Firming Neck Cream Containing N-Acetyl Glucosamine Significantly Improves Signs of Aging on the Challenging Neck and Décolletage.Schlessinger J, Green B, Edison BL, Murphy L, Sabherwal Y. J Drugs Dermatol. 2016 Jan. PMID: 26741381.

2015

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions.Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, Bai H, Gunel M, Lax I, Schlessinger J. Proc Natl Acad Sci U S A. 2015 Dec 29; 2015 Nov 16. PMID: 26630010.
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.Lee S, Greenlee EB, Amick JR, Ligon GF, Lillquist JS, Natoli EJ Jr, Hadari Y, Alvarado D, Schlessinger J. Proc Natl Acad Sci U S A. 2015 Oct 27; 2015 Oct 12. PMID: 26460020.
Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain.Kobashigawa Y, Amano S, Yokogawa M, Kumeta H, Morioka H, Inouye M, Schlessinger J, Inagaki F. Genes Cells. 2015 Oct; 2015 Aug 24. PMID: 26300540.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R. Br J Dermatol. 2015 Oct. PMID: 26149717.
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R. Nat Genet. 2015 Sep; 2015 Jul 27. PMID: 26214590.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K. Lancet. 2015 Aug 8; 2015 Jun 10. PMID: 26072109.
FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis.Perry RJ, Lee S, Ma L, Zhang D, Schlessinger J, Shulman GI. Nat Commun. 2015 Apr 28; 2015 Apr 28. PMID: 25916467.
Improved survival of patients with hypermutation in uterine serous carcinoma.Santin AD, Bellone S, Centritto F, Schlessinger J, Lifton R. Gynecol Oncol Rep. 2015 Apr; 2015 Jan 24. PMID: 26076146.
Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T. J Clin Endocrinol Metab. 2015 Mar; 2014 Dec 9. PMID: 25490274.
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J. Sci Signal. 2015 Jan 20; 2015 Jan 20. PMID: 25605972.
The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.Reshetnyak AV, Opatowsky Y, Boggon TJ, Folta-Stogniew E, Tome F, Lax I, Schlessinger J. Mol Cell. 2015 Jan 8; 2014 Dec 24. PMID: 25544564.
Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J. Pediatr Dermatol. 2015 Jan-Feb; 2014 Nov 21. PMID: 25412565.

2014

Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J. J Drugs Dermatol. 2014 Nov. PMID: 25607706.
Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J, Lemke G. Elife. 2014 Sep 29; 2014 Sep 29. PMID: 25265470.
Secukinumab in plaque psoriasis--results of two phase 3 trials.Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C. N Engl J Med. 2014 Jul 24; 2014 Jul 9. PMID: 25007392.
The docking protein FRS2α is a critical regulator of VEGF receptors signaling.Chen PY, Qin L, Zhuang ZW, Tellides G, Lax I, Schlessinger J, Simons M. Proc Natl Acad Sci U S A. 2014 Apr 15; 2014 Apr 2. PMID: 24706887.
The EGFR family: not so prototypical receptor tyrosine kinases.Lemmon MA, Schlessinger J, Ferguson KM. Cold Spring Harb Perspect Biol. 2014 Apr 1; 2014 Apr 1. PMID: 24691965.
Receptor tyrosine kinases: legacy of the first two decades.Schlessinger J. Cold Spring Harb Perspect Biol. 2014 Mar 1; 2014 Mar 1. PMID: 24591517.
Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers.Opatowsky Y, Lax I, Tomé F, Bleichert F, Unger VM, Schlessinger J. Proc Natl Acad Sci U S A. 2014 Feb 4; 2014 Jan 21. PMID: 24449920.
Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.Schlessinger J, Dover JS, Joseph J, Monheit G, Nelson DB, Albright CD, Axford-Gatley RA, Cohen JL. Dermatol Surg. 2014 Feb; 2013 Dec 26. PMID: 24372978.

2013

Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM, Tome F, Suzuki Y, Sidhu SS, Lax I, Schlessinger J. Proc Natl Acad Sci U S A. 2013 Oct 29; 2013 Oct 14. PMID: 24127596.
Tony Pawson (1952-2013).Schlessinger J. Cancer Cell. 2013 Sep 9. PMID: 24159606.